Cereno Scientific AB (FRA:4A1) PB Ratio: 6.31 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4A1 Cereno Scientific AB FRA:4A1
39 GF Score
Price €0.43
! 3 Warning Signs
View Full Analysis

What is Cereno Scientific AB PB Ratio?

Cereno Scientific AB FRA:4A1 +4.69% 39 PB Ratio is 6.31 as of Aug. 02, 2026. GuruFocus rates FRA:4A1 with a GF Score™ of 39/100. The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Cereno Scientific AB ranks worse than 88.73% on this metric.

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-02), Cereno Scientific AB's share price is €0.4288. Cereno Scientific AB's Book Value per Share for the quarter that ended in Mar. 2026 was €0.07. Hence, Cereno Scientific AB's PB Ratio of today is 6.31.

The historical rank and industry rank for Cereno Scientific AB's PB Ratio or its related term are showing as below:

FRA:4A1' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 6.85
Current: 6.77

During the past 11 years, Cereno Scientific AB's highest PB Ratio was 6.85. The lowest was 0.00. And the median was 0.00.

FRA:4A1's PB Ratio is ranked worse than
88.73% of 923 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs FRA:4A1: 6.77

During the past 12 months, Cereno Scientific AB's average Book Value Per Share Growth Rate was 19.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -17.80% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -15.10% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 4.20% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of Cereno Scientific AB was 186.40% per year. The lowest was -25.00% per year. And the median was -13.00% per year.

Back to Basics: PB Ratio


Cereno Scientific AB  (FRA:4A1) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Cereno Scientific AB PB Ratio Related Terms


Cereno Scientific AB PB Ratio Historical Data

* Premium members only.

The historical data trend for Cereno Scientific AB's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cereno Scientific AB PB Ratio Chart

Cereno Scientific AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.96 1.31 5.36 7.77 8.47

Cereno Scientific AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.27 16.89 13.08 8.47 9.55

FRA:4A1 vs ZTS: PB Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cereno Scientific AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cereno Scientific AB PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cereno Scientific AB's PB Ratio distribution charts can be found below:

* The bar in red indicates where Cereno Scientific AB's PB Ratio falls into.


FRA:4A1
39GF Score
Cereno Scientific AB FRA:4A1
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cereno Scientific AB PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Cereno Scientific AB's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=0.4288/0.068
=6.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Frequently Asked Questions Learn more about PB Ratio →
What does a PB Ratio of 6.31 mean?
Cereno Scientific AB (FRA:4A1) has a PB Ratio of 6.31 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cereno Scientific AB and its competitors. According to the industry distribution chart, Cereno Scientific AB ranks #819 out of 923 companies in the Drug Manufacturers industry, placing it in the top 88.7%.
Is Cereno Scientific AB's PB Ratio too high?
Cereno Scientific AB's current PB Ratio is 6.31. The Drug Manufacturers industry median PB Ratio is 1.88. Cereno Scientific AB's value of 6.31 is 235.6% above this industry median. Based on the distribution chart, Cereno Scientific AB ranks #819 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cereno Scientific AB has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Cereno Scientific AB's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cereno Scientific AB ranks #819 out of 923 companies for PB Ratio. This places Cereno Scientific AB in the lower half of its industry. The industry median PB Ratio is 1.88. Cereno Scientific AB's value of 6.31 is 235.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.88, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cereno Scientific AB's current PB Ratio of 6.31 is 235.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Cereno Scientific AB and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cereno Scientific AB's current PB Ratio is 6.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cereno Scientific AB stock overvalued right now?
Cereno Scientific AB (FRA:4A1) has a current PB Ratio of 6.31. The current PB Ratio is 6.31 and 235.6% above the Drug Manufacturers industry median of 1.88. Cereno Scientific AB's overall GF Score™ is 39/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Cereno Scientific AB (FRA:4A1), the current PB Ratio is 6.31 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cereno Scientific AB Business Description

Other Exchanges CRNO B:Sweden
Address Forandringens gata 10, Molndal, SWE, 431 53
Cereno Scientific AB is developing a pipeline of preventive therapeutics to treat cardiovascular and rare diseases by epigenetic modulation through histone deacetylase inhibition (HDACi). The company's program, CS1, is a phase two dual-acting antithrombotic drug aimed at venous thrombosis and stroke prevention for atrial fibrillation. It also evaluates the potential of epigenetic modulation for rare diseases related to pulmonary fibrosis, thrombosis, inflammation, and high blood pressure in the pulmonary circulation system.
39GF Score

Get the complete analysis for FRA:4A1

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.43
Price